I agree that this site is using cookies. You can find further informations here.
X
Selle, Frédéric
93  results:
Search for persons X
?
1

Bevacizumab, olaparib, and durvalumab in patients with rela..:

Freyer, Gilles ; Floquet, Anne ; Tredan, Olivier...
Nature Communications.  15 (2024)  1 - p. , 2024
Link: https://doi.org/10.1038/..
 
?
2

Neoadjuvant and adjuvant pembrolizumab in advanced high-gra..:

Ray-Coquard, Isabelle L. ; Savoye, Aude-Marie ; Schiffler, Camille...
Nature Communications.  15 (2024)  1 - p. , 2024
Link: https://doi.org/10.1038/..
 
?
3

Author Correction: Bevacizumab, olaparib, and durvalumab in..:

Freyer, Gilles ; Floquet, Anne ; Tredan, Olivier...
Nature Communications.  15 (2024)  1 - p. , 2024
Link: https://doi.org/10.1038/..
 
?
4

A phase II, multicenter, open-label study of abemaciclib an..:

Ottenbourgs, Tine ; van Gorp, Toon ; Kridelka, Frédéric...
International Journal of Gynecologic Cancer.  34 (2024)  4 - p. 627-630 , 2024
Link: https://doi.org/10.1136/..
 
?
5

The association of histopathologic features after neoadjuva..:

Mhawech-Fauceglia, Paulette ; McCarthy, Denis ; Tonooka, Akiko...
Gynecologic Oncology.  186 (2024)  - p. 17-25 , 2024
Link: https://doi.org/10.1016/..
 
?
6

Impact of surgery and chemotherapy in ovarian sex cord-stro..:

Hanvic, Brunhilde ; Lecuru, Fabrice ; Vanacker, Hélène...
Gynecologic Oncology.  174 (2023)  - p. 190-199 , 2023
Link: https://doi.org/10.1016/..
 
?
7

Gestion pratique des inhibiteurs de PARP : Un consensus nat..:

Selle, Frédéric ; Boffa, Jean-Jacques ; Etienne, Gabriel...
Bulletin du Cancer.  109 (2022)  12 - p. 1245-1261 , 2022
Link: https://doi.org/10.1016/..
 
?
8

Efficacy of niraparib by time of surgery and postoperative ..:

O'Cearbhaill, Roisin E. ; Pérez-Fidalgo, Jose-Alejandro ; Monk, Bradley J....
Gynecologic Oncology.  166 (2022)  1 - p. 36-43 , 2022
Link: https://doi.org/10.1016/..
 
?
9

Low probability of disease cure in advanced ovarian carcino..:

You, Benoit ; Van Wagensveld, Lilian ; Tod, Michel...
British Journal of Cancer.  127 (2022)  1 - p. 79-83 , 2022
Link: https://doi.org/10.1038/..
 
?
10

Phase II study of the safety and efficacy of the anti-PD-1 ..:

O'Malley, David M. ; Oaknin, Ana ; Monk, Bradley J....
Gynecologic Oncology.  163 (2021)  2 - p. 274-280 , 2021
Link: https://doi.org/10.1016/..
 
?
11

Chronic fatigue, quality of life and long-term side-effects..:

Gernier, François ; Ahmed-Lecheheb, Djihane ; Pautier, Patricia...
BMC Cancer.  21 (2021)  1 - p. , 2021
Link: https://doi.org/10.1186/..
 
?
12

Patient-centred outcomes and effect of disease progression ..:

Friedlander, Michael ; Moore, Kathleen N ; Colombo, Nicoletta...
The Lancet Oncology.  22 (2021)  5 - p. 632-642 , 2021
Link: https://doi.org/10.1016/..
 
?
13

Efficacy of niraparib by timing of surgery and residual dis..:

O'Cearbhaill, Roisin ; Pérez-Fidalgo, Jose Alejandro ; Monk, Bradley...
Gynecologic Oncology.  162 (2021)  - p. S65 , 2021
Link: https://doi.org/10.1016/..
 
?
14

Real-World Experience of Bevacizumab as First-Line Treatmen..:

Berton, Dominique ; Floquet, Anne ; Lescaut, Willy...
Frontiers in Pharmacology.  12 (2021)  - p. , 2021
Link: https://doi.org/10.3389/..
 
?
15

Fertility preservation, contraception and menopause hormone..:

Rousset-Jablonski, Christine ; Selle, Fréderic ; Adda-Herzog, Elodie...
European Journal of Cancer.  116 (2019)  - p. 35-44 , 2019
Link: https://doi.org/10.1016/..
 
1-15